Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company focused on products and services that prevent and treat disease in farm animals and pets. The ELAN news feed on Stock Titan aggregates company announcements, regulatory updates and other disclosures so readers can follow how Elanco’s strategy and product portfolio evolve over time.
Elanco regularly issues news on pet health innovations, including prescription products for dogs and cats. Recent press releases have covered developments in canine dermatology, such as Zenrelia tablets for control of itching and inflammation associated with skin allergies in dogs and Befrena, an injectable monoclonal antibody targeting canine allergic and atopic dermatitis. The company also reports on its Credelio and Credelio Quattro brands for parasite control in dogs and Credelio CAT for cats, including label expansions, emergency use authorizations and new indications such as protection related to Lyme disease and emerging tick species.
Investors and industry followers will also find farm animal and corporate updates, including quarterly financial results, guidance, restructuring plans and productivity initiatives like Elanco Ascend. News items describe trends in pet health and farm animal revenue, progress in innovation pipelines, changes to manufacturing and R&D footprints, and participation in major healthcare and investor conferences.
This ELAN news page helps readers track how Elanco’s innovation, portfolio and productivity strategy is reflected in product approvals, regulatory milestones, financial performance and strategic partnerships. For anyone monitoring animal health markets, veterinary therapeutics or ELAN stock, it provides a centralized view of the company’s most recent public communications.
Elanco Animal Health has launched the "Unleash Joy" anthem and a music video featuring popular pets to promote their Seresto® collars, which offer eight months of flea and tick protection. The campaign emphasizes responsible pet ownership while encouraging pet owners to enjoy summer activities. Veterinarian David Gosche highlights the balance between fun and the risks of flea and tick-borne diseases during summer. Owners can share their pets' summer adventures on Instagram using the hashtag #SerestoJoinTheJoy.
Elanco Animal Health (NYSE: ELAN) will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13-14, 2022. CFO Todd Young will be featured in a fireside chat on June 13 at 6:20 p.m. ET. Investors can access a live audio webcast via Elanco's investor website, with a replay available for 30 days.
Elanco Animal Health (NYSE: ELAN) will attend the Stifel 2022 Jaws and Paws Conference on June 1, 2022. CEO Jeff Simmons is scheduled to participate in a fireside chat at 3:00 p.m. ET. A live audio webcast of the event will be accessible on Elanco’s investor website, with a replay available for 30 days.
Elanco Animal Health reported Q1 2022 revenue of $1,225 million, a 1% decline year-over-year, but a 2% increase in constant currency. Net income stood at $48 million, up from a $61 million loss in Q1 2021. Adjusted EPS was $0.36, slightly down from $0.37. The company updated its full-year revenue guidance to a range of $4,700-$4,755 million, affected by foreign exchange rates. A strategic alliance with Royal DSM for Bovaer, a methane-reducing product, aims to generate significant future revenue. Despite some market pressures, Elanco remains confident in its growth strategy.
Elanco and Royal DSM have formed a strategic alliance to enhance sustainability in livestock farming by developing the methane-reducing product, Bovaer®, in the U.S. Elanco gains exclusive rights to commercialize the product, which has the potential for over US$200 million in annual revenue in the U.S. alone, contributing to the Global Methane Pledge goal of a 30% emission reduction by 2030. Royal DSM will benefit from royalty income and increased production capacity, promoting a significant environmental impact through reduced methane emissions from cattle.
Elanco Animal Health Incorporated (NYSE: ELAN) is set to announce its first quarter 2022 financial results on May 9, 2022, at 8:00 a.m. eastern time. The announcement will be accompanied by a conference call for investors and media, providing insights into the company's performance. The details of the call will be accessible via a live webcast on Elanco’s website. As a global leader in animal health, Elanco focuses on innovating products and services to improve animal welfare and create value for various stakeholders.
Elanco Animal Health has announced plans for a new global headquarters in
Elanco Animal Health announced a successful tender offer for its 4.272% Senior Notes due 2023, with about $406.4 million (54.19% of total principal) tendered by the April 11, 2022 deadline. The company increased the tender cap from $250 million to $406.4 million. Validly tendered notes will receive a total consideration of $1,035 per $1,000 principal amount. The offer expires on April 25, 2022, and all conditions remain unchanged except for the tender cap increase.
Elanco Animal Health and Ginkgo Bioworks have launched BiomEdit, a new company focused on microbiome innovations for animal health. BiomEdit aims to develop probiotics and other solutions addressing urgent needs in livestock health, including antibiotic resistance. With an initial funding of $40 million, BiomEdit will operate independently, utilizing Elanco’s microbiome R&D expertise and intellectual property. This strategic separation allows Elanco to concentrate more effectively on its late-stage pet health pipeline while facilitating the growth of BiomEdit in the animal health sector.
Elanco Animal Health Incorporated (NYSE: ELAN) has initiated a cash tender offer for up to